ALK bets on well-known tablet technology to treat peanut allergy

ALK has gotten the rights to use a technology by partner Catalent to develop a peanut allergy tablet vaccine. But the Danish allergy company is far from alone on the food allergy market, where biotech firms have been testing a vast array of different technologies in recent years. Still, CEO Carsten Hellmann brushes off competition.

ALK is betting big on peanut allergy | Photo: ALK / PR

ALK has secured the rights to a technology it will use to develop a tablet against peanut allergy, which will be one of the most important growth drivers in the years post-2025, according to the Danish allergy company.

The technology in question is a fast-dissolve tablet formulation dubbed Zydis, which Catalent is behind. ALK has used this technology before, as the company signed a deal with Catalent many years ago to develop its respiratory tablet portfolio.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs